Propranolol therapy for secondary hyperparathyroidism in uraemia.
作者信息
Fournier A, Coevoet B, de Fremont J F, Gueris J, Caillens G, Desplan C, Calmette C, Moukhtar M S
出版信息
Lancet. 1978 Jul 1;2(8079):50-1. doi: 10.1016/s0140-6736(78)91366-1.
PMID:78252
Abstract
摘要
相似文献
1
Propranolol therapy for secondary hyperparathyroidism in uraemia.普萘洛尔治疗尿毒症继发性甲状旁腺功能亢进
Lancet. 1978 Jul 1;2(8079):50-1. doi: 10.1016/s0140-6736(78)91366-1.
2
Comparison of propranolol and atenolol in the control of hyperparathyroidism in uremia.普萘洛尔与阿替洛尔对尿毒症患者甲状旁腺功能亢进控制效果的比较
Adv Exp Med Biol. 1982;151:667-76. doi: 10.1007/978-1-4684-4259-5_68.
3
Blockers of beta and H2 receptors and secondary hyperparathyroidism in uraemia.β受体阻滞剂、H2受体阻滞剂与尿毒症继发性甲状旁腺功能亢进
Proc Eur Dial Transplant Assoc. 1981;18:642-7.
4
Effect of propranolol and metoprolol on parathyroid hormone and calcitonin secretions in uraemic patients.普萘洛尔和美托洛尔对尿毒症患者甲状旁腺激素和降钙素分泌的影响。
Br Med J. 1980 Jun 7;280(6228):1344-6. doi: 10.1136/bmj.280.6228.1344.
5
Acute effects of propranolol and metoprolol on plasma concentrations of parathyroid hormone and calcitonin in uraemic patients.普萘洛尔和美托洛尔对尿毒症患者血浆甲状旁腺激素和降钙素浓度的急性影响。
Proc Eur Dial Transplant Assoc. 1979;16:649-55.
6
Propranolol in uraemic osteodystrophy.普萘洛尔治疗尿毒症性骨营养不良
Lancet. 1979 Feb 17;1(8112):386-7. doi: 10.1016/s0140-6736(79)92929-5.
7
Histamine H2 receptor blockade in patients with hyperparathyroidism.甲状旁腺功能亢进患者的组胺H2受体阻断作用
Am J Nephrol. 1984;4(4):205-7. doi: 10.1159/000166809.
8
9
Propranolol in uraemic osteodystrophy.尿毒症性骨营养不良中的普萘洛尔
Lancet. 1978 Oct 28;2(8096):940. doi: 10.1016/s0140-6736(78)91653-7.
10
[Calcimimetics and secondary uremic hyperparathyroidism. The Danish Society of Nephrology].[拟钙剂与继发性尿毒症性甲状旁腺功能亢进。丹麦肾脏病学会]
Ugeskr Laeger. 2003 Mar 17;165(12):1245.
引用本文的文献
1
Disturbed calcium metabolism in subjects with elevated diastolic blood pressure.
Clin Investig. 1992 Sep;70(9):748-51. doi: 10.1007/BF00180741.
Zotero 插件